Why the study?
Mitochondrial dysfunction is pivotal in CVD development and progression, but the exact role of cardiolipin remodeling in this mechanism remains unclear.
Design
Review
Key result
Pathological cardiolipin remodeling drives mitochondrial dysfunction and accelerates cardiovascular disease progression, making it a promising clinical therapeutic target.
Authors
Loading...
May support cardiolipin remodeling as a therapeutic target in mitochondrial CVD; leaves open need for interventional trials before practice change.
Targeting cardiolipin remodeling pathways may represent a promising therapeutic strategy for cardiovascular diseases driven by mitochondrial dysfunction.
Zhang et al. (2025) conducted a review in Cardiovascular diseases. Cardiolipin-targeted therapies was evaluated. Pathological cardiolipin remodeling drives mitochondrial dysfunction and accelerates cardiovascular disease progression, making it a promising clinical therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: